Introduction
Fucosidosis is a rare and severe genetic condition that is marked by the body’s inability to break down certain complex sugars attached to fat or protein in the cell. This causes an accumulation of these complex sugars within the body organs and in turn affects organs and systems like the brain and the central nervous system.
The symptoms can vary a lot. While some show mild symptoms, others suffer from rapidly progressing and severe symptoms. Fucosidosis is one of approximately 50 diseases that are classified as lysosomal storage disorders. Lysosomal storage disorders involve a genetic variation (mutation) that disrupts the normal functioning of lysosomes. Lysosomes are specialised structures within cells responsible for breaking down waste materials and cellular debris- within the cells.1
As of 2020, less than 200 cases of fucosidosis had been reported worldwide, with an estimated frequency of less than one in 200,000 live births.5 Hence fucosidosis is a challenging condition to diagnose and manage.
There are no approved therapies that can cure fucosidosis currently. Instead, the treatment focuses on managing symptoms by means of an interdisciplinary approach to care, involving different specialists working together to improve the patient’s quality of life.1
Unfortunately, around 60% of affected individuals die before the age of 10. This high mortality rate is mainly due to recurrent lung infections and progressive neurological decline, which are common complications of the disease.2
Overview of Fucosidosis
What are lysosomal storage disorders?
Lysosomes are important cell organelles that contain enzymes responsible for the break down of various molecules, including proteins, nucleic acids, carbohydrates, and lipids.3 People with a lysosomal storage disorder lack one of these enzymes completely or have the enzyme in insufficient quantities.
This deficiency of the enzyme leads to the accumulation of undegraded substances within the lysosomes, causes the cells to malfunction and results in damage to tissues and organs throughout the body.1 Fucosidosis is one such lysosomal storage disorder which is caused by a mutation (changes) in a gene called the FUCA1.2
This gene provides instructions for making the enzyme alpha-L-fucosidase, which is crucial for breaking down fucose-containing glycolipids, glycoproteins, and oligosaccharides. The deficiency or absence of the alpha-L-fucosidase enzyme causes these substances to accumulate within cells, leading to the characteristic symptoms of fucosidosis.
Genetic basis and inheritance patterns of Fucosidosis
Humans beings have 23 pairs of chromosomes, which are structures in cells that contain our genetic material. Genes, the units of heredity, are located on these chromosomes and contain instructions that make us who we are. They control our growth, development and functioning. A child inherits half their genes from their mother and half from their father.4
Fucosidosis is a genetic condition that is inherited in an autosomal recessive pattern, which means that an affected child should have inherited one defective copy of the FUCA1 gene from each of the parents.1
The alpha-L-fucosidase enzyme helps with the breakdown of certain complex sugars attached to protein and fat. In a healthy person, this enzyme helps to degrade fucose-containing molecules, preventing their accumulation in cells.
However, in individuals with fucosidosis, mutations in the FUCA1 gene disrupt the normal functioning of alpha-L-fucosidase. Therefore, the enzyme is either produced in insufficient quantities or is entirely non-functional, leading to the buildup of complex sugars in the cells. Over time, this accumulation causes cellular damage and manifests into the symptoms associated with the disease.2
What is autosomal recessive?6
The term "autosomal" implies that the gene responsible for fucosidosis is located on one of the first 22 pairs of chromosomes, and are not involved in determining an individual’s sex. "Recessive" means that both genes of the individual are mutated. If a person inherits only one copy of the mutated gene, they are considered a carrier. Carriers do not usually show any symptoms of the disease, as the single functioning copy of the gene is sufficient to maintain normal enzyme activity.
Symptoms
Children with fucosidosis usually show symptoms immediately after birth. However, in some cases, the symptoms might develop later in childhood. The severity of symptoms can vary widely among individuals. The common symptoms of fucosidosis include:1
- Intellectual disability: Children with fucosidosis show learning difficulties and delayed cognitive development.
- Delayed development of motor skills: Developmental milestones such as crawling, walking, and speaking are usually delayed.
- Slow or impaired growth: Affected individuals may find it difficult to gain weight and grow at a normal rate.
- Abnormal skeletal development: Children with fucosidosis frequently show skeletal abnormalities.
- Seizures: Epileptic seizures are a common neurological symptom of fucosidosis and can vary in severity and frequency.
- Abnormal muscle contraction: Stiff and awkward movements are seen.
- Distinct facial features: Many children with fucosidosis develop characteristic facial features like a prominent forehead, thick lips, and an enlarged tongue.
- Recurrent respiratory infections: The accumulation of mucus can lead to frequent lung infections.
- Clusters of small, dark red spots on the skin: These spots called angiokeratomas are usually found on the body.
- Enlargement of certain internal organs: Organs such as the liver and spleen may become enlarged.
Diagnosis
Diagnosis of fucosidosis is based on clinical symptoms, signs, biochemical tests, and genetic analysis. These biochemical tests measure the levels of fucosylated oligosaccharides and glycoproteins.
The process begins with a detailed assessment of the symptoms and medical history. If a possibility of fucosidosis is seen, biochemical tests show a significant increase of fucosylated oligosaccharides and glycoproteins in the urine. When combined with a reduction in alpha-L-fucosidase enzyme activity in the blood, these results strongly suggests fucosidosis. To confirm the diagnosis, genetic testing can be performed to identify mutations in the FUCA1 gene. Genetic testing is useful for distinguishing fucosidosis from other lysosomal storage disorders that may have similar symptoms.
Therapeutic approaches7
- Supportive and Multidisciplinary Care: The primary approach to managing fucosidosis is supportive care which focuses on managing symptoms and improving the overall quality of life. This usually involves a team including metabolic physicians, physiotherapists, and specialists in ophthalmology, orthopaedics, and cardiology. Other allied health services, such as speech therapy and occupational therapy, may also be involved in the care of individuals with fucosidosis.
- Hematopoietic Stem Cell Transplantation (HSCT): HSCT is a potential treatment option for fucosidosis, particularly when performed early in the course of the disease. HSCT involves the transplantation of healthy stem cells, which can develop into new blood cells that produce the missing or deficient enzyme. Studies have shown that early transplantation can be more effective, as it may prevent or slow the progression of symptoms. After successful transplantation, a gradual increase in alpha-L-fucosidase levels in the plasma has been observed, suggesting a therapeutic benefit.
- Enzyme Replacement Therapy (ERT): ERT for fucosidosis is currently in the preclinical stages of development. Researchers are investigating the feasibility of delivering a recombinant enzyme directly to the central nervous system in animal models. This approach aims at potentially slowing or halting the progression of the disease. While ERT offers hope for future treatment, it is still in the experimental phase, and clinical trials in humans have not yet been conducted.
- Gene therapy: Gene therapy is another promising avenue for treating fucosidosis. This approach involves introducing a functional copy of the FUCA1 gene into the patient’s cells, potentially correcting the underlying genetic defect. Although no clinical trials for gene therapy in fucosidosis have been completed to date, ongoing research in this area offers hope for future therapeutic options.
FAQs
What are the chances that two carrier parents would have a child affected with Fucosidosis?5
If both parents are carriers of the mutated FUCA1 gene, there is a 25% chance that the child will have mutation in both their genes and have fucosidosis. There is a 50% chance that the child may inherit only one mutated gene, making the child a carrier without symptoms.
What causes genetic mutations?6
Genetic mutations can be hereditary i.e., passed down from parents to their children, or may occur spontaneously. Environmental factors like radiation or chemicals can also cause genetic mutations.
Are there any symptoms that a carrier may show?8
Individuals who carry one copy of the mutated FUCA1 gene usually do not show any symptoms of fucosidosis because the single functional copy of the gene usually produces enough alpha-L-fucosidase enzyme to prevent the buildup of complex sugars in the cells. Hence carriers are generally healthy and may be unaware that they carry the mutation.
Summary
Fucosidosis is a rare genetic condition caused by mutations in the FUCA1 gene. This mutation affects the normal function of the alpha-L-fucosidase enzyme in the lysosome and leads to the accumulation of sugars in the body.
Fucosidosis is inherited in an autosomal recessive pattern and causes a wide range of symptoms and vary in severity, affecting:
- physical development,
- neurological function, and
- overall health.
Diagnosis is based on clinical assessments, biochemical testing, and genetic analysis. Though there is no cure.Currently treatment include supportive care, and haematopoietic stem cell transplantation. Emerging therapies like enzyme replacement and gene therapy offer hope for improving patient outcomes.
References
- Fucosidosis | boston children’s hospital [Internet]. [cited 2024 Aug 20]. Available from: https://www.childrenshospital.org/conditions/fucosidosis#:~:text=Fucosidosis%20is%20a%20rare%20genetic,brain%20and%20central%20nervous%20system.
- Kaur A, Dhaliwal AS, Raynes H, Naidich TP, Kaufman DM. Diagnosis and supportive management of fucosidosis: a case report. Cureus [Internet]. [cited 2024 Aug 20];11(11):e6139. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6907717/
- Cooper GM. Lysosomes. In: The Cell: A Molecular Approach 2nd edition [Internet]. Sinauer Associates; 2000 [cited 2024 Aug 21]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK9953/
- MPS Society [Internet]. [cited 2024 Aug 21]. Fucosidosis. Available from: https://mpssociety.org.uk/conditions/related-conditions/fucosidosis
- Orphanet: fucosidosis [Internet]. [cited 2024 Aug 21]. Available from: https://www.orpha.net/en/disease/detail/349
- Fucosidosis | about the disease | gard [Internet]. [cited 2024 Aug 21]. Available from: https://rarediseases.info.nih.gov/diseases/6473/fucosidosis
- Stepien KM, Ciara E, Jezela-Stanek A. Fucosidosis—clinical manifestation, long-term outcomes, and genetic profile—review and case series. Genes [Internet]. 2020 Nov [cited 2024 Aug 21];11(11):1383. Available from: https://www.mdpi.com/2073-4425/11/11/1383
- Available from: https://kidshealth.org/en/teens/carrier-genetic-condition.html#:~:text=A%20person%20who%20has%20or,carriers%20don%27t%20have%20symptoms.

